Literature summary for 3.4.14.5 extracted from

Mistry, G.C.; Bergman, A.J.; Luo, W.L.; Cilissen, C.; Haazen, W.; Davies, M.J.; Gottesdiener, K.M.; Wagner, J.A.; Herman, G.A.
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects (2007), J. Clin. Pharmacol., 47, 159-164.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	the pharmacokinetics of rosiglitazone will not be altered when coadministered with sitagliptin in patients with type 2 diabetes	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Synonyms

Synonyms	Comment	Organism
dipeptidyl peptidase-4	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)